Adrenoleukodystrophy Epidemiology Forecast to 2030

Adrenoleukodystrophy Epidemiology Forecast to 2030

“Delveinsight Business Research”
DelveInsight’s ‘Adrenoleukodystrophy Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Adrenoleukodystrophy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Adrenoleukodystrophy (ALD) is an X-linked recessive genetic disorder caused by the abnormality in the ABCD1 gene present on the X chromosome that leads to the accumulation of very-long-chain fatty acids (VLCFAs) in the brain, nervous system, and adrenal gland. The accumulation of VLCFAs leads to the deterioration of the myelin sheath, and without the sheath, neurons cannot conduct action potentials, this leads to the development of seizures and hyperactivity.

The disease mainly affects males (hemizygotes), but similar to other X-linked disorders, it is increasingly recognized that females (heterozygotes) may be clinically affected as well.

The main neurological manifestations include a progressive, fatal, inflammatory cerebral leukodystrophy (cerebral adrenoleukodystrophy) most frequently appearing in young boys, and a slowly progressive, non-inflammatory axonal myelopathy and peripheral neuropathy (adrenomyeloneuropathy, AMN), that occurs in most adult males. Many females develop myeloneuropathy as well, but usually at a later stage and with milder symptoms than seen in males. Furthermore, the disorder manifests with primary adrenal failure (PAI) in more than half of the males that are usually not seen in females.

The DelveInsight Adrenoleukodystrophy epidemiology report gives a thorough understanding of the Adrenoleukodystrophy by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Adrenoleukodystrophy in the US, Europe, and Japan. The report covers the detailed information of the Adrenoleukodystrophy epidemiology scenario in seven major countries (US, EU5, and Japan).

 

Key Highlights Of The Report

In 2017, the total prevalent population of Adrenoleukodystrophy in the 7MM was 55,242.

The estimates show the highest diagnosed prevalence of Adrenoleukodystrophy in the United States with 4,885 cases in 2017.

Among the European 5 countries, Germany had the highest diagnosed prevalent population of Adrenoleukodystrophy, followed by France and the United Kingdom. On the other hand, Spain had the lowest diagnosed prevalent population.

As per DelveInsight’s analysis, a higher percentage of diagnosed prevalence was observed for females, in comparison to males, in all the 7MM countries during the study period (2017–2030).

 

Request for Sample Pages: 

https://www.delveinsight.com/sample-request/adrenoleukodystrophy-epidemiology

 Adrenoleukodystrophy Epidemiology

Adrenoleukodystrophy Epidemiology

Delveinsight’s Adrenoleukodystrophy epidemiology division provides insights about historical and current patient pool and forecasted trends for every seven major countries. 

The Adrenoleukodystrophy epidemiology data are studied through all possible divisions to give a better understanding of the Disease scenario in 7MM. 

The Adrenoleukodystrophy epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. 

It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

 

Scope of the Report

  • The report provides insight into the historical and forecasted patient pool of Adrenoleukodystrophy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.

  • The report assesses the disease risk and burden and highlights the unmet needs of Adrenoleukodystrophy.

  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.

  • The Adrenoleukodystrophy report provides a detailed overview explaining Adrenoleukodystrophy causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.

  • The Adrenoleukodystrophy Epidemiology Report and Model provide an overview of the risk factors and global trends of Adrenoleukodystrophy in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan).

  • The report provides the segmentation of the Adrenoleukodystrophy epidemiology. 

 

Key Questions Covered In The Adrenoleukodystrophy Report Include:

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Adrenoleukodystrophy?

  • What are the key findings pertaining to the Adrenoleukodystrophy epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?

  • What would be the total number of patients of Adrenoleukodystrophy across the 7MM during the forecast period (2017-2030)?

  •  Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?

  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?

  • What is the disease risk, burden and unmet needs of the Adrenoleukodystrophy?

  • What are the currently available treatments of Adrenoleukodystrophy?

 

Key Benefit of Adrenoleukodystrophy Epidemiology Report 

  • The Adrenoleukodystrophy Epidemiology report will allow the user to –

  • Develop business strategies by understanding the trends shaping and driving the global Adrenoleukodystrophy market

  • Quantify patient populations in the global Adrenoleukodystrophy market to improve product design, pricing, and launch plans

  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Adrenoleukodystrophy therapeutics in each of the markets covered

  • Understand the magnitude of Adrenoleukodystrophy population by its epidemiology

  • The Adrenoleukodystrophy Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

 

Table of Contents

  1. Key Insights 

  2. Executive Summary of Adrenoleukodystrophy

  3. Adrenoleukodystrophy Disease Background and Overview

  • Adrenoleukodystrophy Sign and Symptoms

  • Adrenoleukodystrophy Pathophysiology

  • Adrenoleukodystrophy Risk Factors

  • Adrenoleukodystrophy Diagnosis

  1. Adrenoleukodystrophy Patient Journey

  2. Adrenoleukodystrophy Epidemiology and Patient Population

  3. Adrenoleukodystrophy Treatment Algorithm, Current Treatment, and Medical Practices

  4. KOL Views on Adrenoleukodystrophy 

  5. Adrenoleukodystrophy Unmet Needs

  6. Appendix

  7. DelveInsight Capabilities

  8. Disclaimer

*The table of contents is not exhaustive; will be provided in the final report

About  DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

 

Adrenoleukodystrophy Market Insight, Epidemiology and Market Forecast 2030
DelveInsight’ s Adrenoleukodystrophy Market Insights, Epidemiology and Market Forecast 2030 report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology.

 

Adrenoleukodystrophy Pipeline Insights, 2020

Adrenoleukodystrophy Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Adrenoleukodystrophy market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/